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Multisample, nonindexed pooling combined with next-generation sequencing (NGS) was used to discover RET proto-oncogene
sequence variation within a cohort known to be unaﬀected by multiple endocrine neoplasia type 2 (MEN2). DNA samples (113
Caucasians, 23 persons of other ethnicities) were ampliﬁed for RET intron 9 to intron 16 and then divided into 5 pools of <30
samples each before library prep and NGS. Two controls were included in this study, a single sample and a pool of 50 samples
that had been previously sequenced by the same NGS methods. All 59 variants previously detected in the 50-pool control were
present. Of the 61 variants detected in the unaﬀected cohort, 20 variants were novel changes. Several variants were validated by
high-resolution melting analysis and Sanger sequencing, and their allelic frequencies correlated well with those determined by
NGS. The results from this unaﬀected cohort will be added to the RET MEN2 database.
1.Introduction
Multiple endocrine neoplasia type 2 (MEN2) is a rare
autosomal dominant inherited disorder with a high lifetime
risk of medullary thyroid carcinoma (MTC) [1, 2]. MEN2
consists of three syndromes: familial medullary thyroid
carcinoma (FMTC), MEN2A, and MEN2B [1, 3]. FMTC
families have only MTC. MEN2A families have MTC, with
at least one individual developing pheochromocytomas,
parathyroid hyperplasia, or both. MEN2B patients have
MTC (with or without pheochromocytoma) and other
characteristic clinical features: mucosal ganglioneuromas,
GI ganglioneuromas, eye abnormalities, and skeletal abnor-
malities including marfanoid body habitus [4–7]. MEN2 is
caused by pathogenic mutations found exclusively within
the RET proto-oncogene (REarranged during Transfection).
These are gain-of-function dominant mutations which are
commonly heterozygous missense mutations found at spe-
ciﬁc codons within RET exons 10, 11, and 13–16 and
rarely found within exons 5 and 8 [1, 8–10]. The medical
management for the patient and potentially their family
members is based on the familial RET variation, which
is usually determined by Sanger sequencing [1]. Discovery
of a known MEN2 pathogenic RET mutation within a
family leads to screening for MTC, pheochromocytomas, or
parathyroid hyperplasia, and potentially prophylactic thy-
roidectomy to increase survival rate for the intractable,
aggressive MTC. Approximately 75–80% of MTC patients
have the sporadic form of MTC (i.e., isolated, nonfamilial
MTC), not MEN2 [6]. Patients with apparent sporadic
MTC are always tested for an RET germline mutation, in
case they actually have MEN2 and require diﬀerent med-
ical management. Although there are many well-known
pathogenic RET mutations causative of MEN2, it may be
diﬃcult to know if a rare or novel germline RET variant is a
pathogenic mutation (patient has MEN2) or nonpathogenic
polymorphism (patient has sporadic MTC).
Interpretation of rare and novel variants will increase
in importance as more people are sequenced at the exome,
whole genome, or targeted gene levels. Many new changes
will be found with unknown clinical signiﬁcance and their
presence and allele frequency within the general population2 Journal of Thyroid Research
is of importance to help determine pathogenicity status of a
variant. Consortiums like the 1000 genome and other large
sequencing projects are making great progress in under-
standing population sequence variation. Yet more direct
studies on single genes or gene panels can yield higher
sequencingreadcoverageandmorecost-eﬀectivesequencing
over a smaller genetic area. Also, a particular chosen cohort
can be sequenced for a particular locus, such as in the
case of this study, where a cohort that was self-reported to
have no personal or family history of MEN2 or MTC was
sequenced for a section of the RET protooncogene where
most pathogenic MEN2 causative mutations are located.
RET sequence variation detected in this MEN2 unaﬀected
population can then be added to the MEN2 RET database
[8]. This data could be used for several reasons: (1) to
help interpret the pathogenicity of clinically detected RET
sequence variation; (2) as a reference for any future MEN2
case studies (variant was not found in those unaﬀected by
MEN2disease);(3)forimprovedgenetictestdesign,toavoid
or minimize designing probes or primers over known RET
sequence variation.
To further reduce costs of sequencing large numbers
of individuals, multiple samples can be pooled (without
indexing) before next-generation sequencing (NGS). This
was the focus of several studies that analyzed the ability
to detect true variants within nonindexed pooled sample
sets [11–16]. Thirty samples (60 alleles) were the maximum
pooling number indicated by our prior studies and in other
reports [12, 14, 17, 18], for reproducible and accurate
singleton allele detection within the pool (a singleton is
a unique allele within the pool). A pool of this size was
expected to a have a singleton allele read frequency of
1.67%, and with consideration of sequencing error rates
and potential variance in NGS determined variant read
frequencies, singleton variants are expected to be detected
above a cutoﬀ of >1% variant reads [17, 18].
In this study, 136 individuals of an MEN2 unaﬀected
cohort were sequenced on the illumina genome analyzer
utilizing laboratory and bioinformatics protocols from our
previous studies for nonindexed, multiple sample pooling.
The pool size was limited to less than 30, which is the
previously determined optimal pooling size for accurate
singleton variant detection [12, 14, 17, 18]. In total, 61
variants were detected within the MEN2 unaﬀected cohort,
which included 20 novel variants.
2.MaterialsandMethod
2.1. Samples. Peripheral blood samples from 136 adult
volunteers (113 Caucasian and 23 non-Caucasians for ethnic
diversity) were collected and deidentiﬁed using University of
Utah IRB protocol no. 7740. The donors for this unaﬀected
cohort were self-described as not having a personal or family
history of neither medullary thyroid carcinoma nor multiple
endocrine neoplasia type 2 (MEN2). The 51 samples used
as controls were deidentiﬁed according to IRB no.7275 and
were Sanger sequenced for RET exons 10, 11, and 13–
16, including exon/intron boundaries. The “single-sample
control” did not have RET mutations causative of MEN2,
while the “50 pool” control contained many samples with
known MEN2 causative RET mutations. The 50 pool control
wassequencedontheilluminagenomeanalyzerseveraltimes
previously [17, 18].
2.2. PCR, Library Prep, and NGS. DNA samples were
ampliﬁed from RET intron 9 to intron 16 using long-range
PCR technology. Amplicons were normalized by SequalPrep
(Invitrogen Corp, Carlsbad, CA), quantiﬁed using Quant-
iT Picogreen dsDNA kit (Invitrogen Corp), and equimolar
pooled before Illumina Library Prep, utilizing previously
described protocols [18]. Between 27 and 29 Caucasian
samples’ amplicons were combined into four separate pools
(P1, P2, P3, and P4) before Illumina Library Prep and NGS.
The non-Caucasian cohort’s 23 samples were sequenced in
a separate pool (ethnic pool). The PCR-ampliﬁed RET posi-
tions 1–9180 are positions 43608691–43617870 in reference
sequence NC 000010.10 (Table 1) .T w oc o n t r o l sw e r ea l s o
included in this study, a single sample and also a pool of
50 samples. Each pool and each control were sequenced in a
separateﬂowcelllaneontheilluminagenomeanalyzer,using
single-end read chemistry.
2.3. Data Analysis. Sequencing image ﬁles were processed
and reads aligned to the RET reference sequence with
SeqMan NGen version 2.1 software (DNAstar, Madison,
WI), as described previously [17, 18] .R e a d su s e dw e r eo f
67 base lengths since the 3  end read positions of longer
reads can have an increase in sequencing background errors,
as shown in previous studies [17, 19, 20]. As previously
described,severalbasequalityscorescreeningthresholds(Q-
threshold) evaluated for read coverage, errors (especially for
outlier errors, which could be mistaken for false positives
in a pool), variant read percentage, and base quality score
statistics to determine the 30 Q-threshold should be used
for analysis of all data sets, which minimized errors while
maintaining adequate target read coverage (data not shown)
[17, 18].
Excluded from analysis was a region of repeats and
homopolymers that caused misalignment errors in all data
sets (designated “repeat region,” amplicon positions 7686 to
7720). Changes from the reference sequence were designated
variants, and the variant read percentage is the NGS-
determined allele frequency. The previously developed sub-
tractive correction method of variant detection was applied
wherein the control’s variant read percentages (at every
positionandpossiblevariantchange)aresubtractedfromthe
pooled data’s variant read percentages, to yield a pooled data
set without background sequencing error [17, 18].
2.4. Variant Validation. AsubsetoftheNGS-detectedRET se-
quencevariantswerevalidatedbyeitherhigh-resolutionmelt-
ing analysis (HRM) and/or Sanger sequencing. The HRM
analysis PCR primers for RET exons 13 and 15 were de-
scribed previously [21]. RET intron 9 used HRM analysis
primers (5  to 3 ): forward ACA CTG CAA TGT GCG
GGT CA and reverse GTC CCC CAA CAA TGC TGC CC.Journal of Thyroid Research 3
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Sample DNA (∼5 to 15ng/uL ﬁnal concentration) was
ampliﬁed and analyzed as described previously [21], except
theLightScanner32instrument(IdahoTechnology,Inc.,Salt
Lake City, UT) which was used for both PCR and HRM
analysis. The LightScanner parameters included Uracil-DNA
glycosylase step (50◦C for 10min); polymerase activation
(95◦C for 10min); 40 PCR cycles (denaturation at 95◦Cf o r
1s, annealing at 62◦C for 1s, extension at 72◦Cf o r4 s ) ;
formation of amplicon heteroduplexes (95◦C for 1s, then
cool rapidly to 40◦C for 10s with ramp rate of 20◦C/s);
high-resolution melting protocol (70 to 96◦Cw i t hr a m p
rate of 0.3◦C/s) [21]. In order to detect samples with a
homozygous RET variant that could not be distinguished
from homozygous wild-type samples during HRM analysis,
the same procedure was performed, except wild-type DNA
(∼5ng/uL ﬁnal concentration) which was spiked into the
PCR reaction [22]. If needed, Sanger sequencing was used
to conﬁrm HRM determined variant results.
3. Results
3.1. Next-Generation Sequencing (NGS) of the 50-Pool and
Single-Sample Controls. The sequence of the single-sample
control used in this study exactly matched the reference
sequence and therefore had no true variant changes from
the reference sequence, only background sequencing error
(Table 1). This sample was an ideal control for error
rates since any variant reads from the RET reference at
each sequence position reﬂects the background NGS error
rates, and also illumina genome analyzer sequencing has
demonstrated reproducible, nonuniform, sequence-speciﬁc
background error rates, read coverage, and base quality
scores between lanes and runs using the same version
chemistry [11, 12, 17–20, 23, 24]. This single sample controls
for the sequence-speciﬁc error rates within the pooled data
sets by using the subtractive correction method, as described
in our previous studies [17, 18]. For subtractive correction,
the single-sample control’s variant reads at every possible
sequence position, and change from the reference sequence
is subtracted from the pool’s variant read percentages. This
yields an estimation of the pooled data without background
sequencing error rates contributing to the variant read per-
centages (examples in Figure 1). The single-sample control
and 50-pool data were also used for selection of the 30
Q-threshold used for quality screening of the data before
analysis (data not shown) [17, 18].
The 50-pool control demonstrated sensitivity to detect
known variants with low read percentages for this NGS run
and for using the subtractive correction method (as shown
in Figure 1). The 50-pool contained 100 alleles and had an
expected 1% singleton variant read frequency (singleton is
unique within the pool). All 59 variants previously detected
in the 50-pool were present at >0.5% variant reads and at
similar percentage variant read values as determined in a
previous NGS run with the same library (R2 = 0.9991,
Figure 1(a)). The 50-pool data had some potential false
positives around the cutoﬀ of 0.5% variant reads but
after subtractive correction with the single-sample control
data, and all true variants were readily detected from the
background error (Figure 1(b)).
3.2. NGS of MEN2 Unaﬀected Cohort. Based on our previous
work and other studies, sample pools were restricted to
30 or less samples within each pool to result in a variant
read percentage above 1%, the chosen cutoﬀ for the most
accurate singleton variant detection [12, 14, 17]. The 113
Caucasian samples were divided into 4 pools with less than
30 samples. Caucasian pool P1 had 27 samples, P2 had 29,
P3 had 28, and P4 had 29 samples, with an expected 1.85%,
1.72%, 1.77%, and 1.72% singleton variant read frequency,
respectively. All pool data sets were evaluated with and
without subtractive correction of sequencing background
error rates using the single-sample control (Figure 1(c) and
data not shown). A total of 51 variants were detected in the
Caucasian MEN2 unaﬀected cohort with >1% variant read
values, of which 23 were not found in the non-Caucasian
MEN2 unaﬀected cohort (ethnic pool) (Table 1). The lowest
singleton variant in the Caucasian data sets was in P2
with 1.12% variant read frequency. The 23 non-Caucasian
samples were in one pool (ethnic pool), with an expected
2.17% singleton allele read frequency. A total of 38 variants
were detected in this ethnically diverse MEN2 unaﬀected
cohort with >1% variant read values, of which 10 were
not found in the Caucasian data sets. The lowest singleton
variant in the ethnic pool had 1.79% variant read frequency.
The variant read percentages for each detected variant is
shown in Table 1 per pool and also summarized for the four
Caucasian pools. For comparison, the NCBI dbSNP allele
frequency values for detected variants are also shown. All
variants detected were intronic changes, except the expected
common polymorphisms found in exons 11, 13, 14, and
15. Of the total 61 variants found in the MEN2 unaﬀected
cohort, 20 variants were novel changes, not seen in the 50-
pool control or in NCBI dbSNP132.
3.3. Validation of NGS-Detected Variations. Since the 136
unaﬀected cohort samples had not been sequenced previ-
ously by either Sanger or NGS methods, several variant loca-
tions within three pools (total of 79 samples) were chosen
for validation. The high-resolution melting (HRM) analysis
method, which is a rapid, closed-tube mutation scanning
assay, was chosen to genotype each individual sample for
validationofNGSvariantdetectionandtheNGSdetermined
variant allele frequency (Table 2). High-resolution melting
analysis detects sequence variation within the PCR amplicon
using a saturating dsDNA dye and in many cases can
uniquely identify each variant based on diﬀerential melting
proﬁles (Figure 2(a))[ 25–28]. HRM assay states 100% speci-
ﬁcity and sensitivity for detection of heterozygous variants
within small amplicons (<300bp) [29]. HRM analysis was
used to detect sequence variations within a section of RET
intron 9 and exons 13 and 15 (Figure 2 and data not
shown). RET exons 13 and 15 were chosen since they each
contain a common polymorphism present in all pools that
could be detected using the previously developed HRM6 Journal of Thyroid Research
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Figure 1: Variant identiﬁcation in the 50-pool control and Caucasian P2 pool. (a) Variant read percentages for variants detected in the
50-pool control below 10% variant reads are shown. The variants detected in the 50-pool data for the current NGS run (Y-axis) is compared
to the same library sequenced previously in a diﬀerent NGS run (X-axis) with trendline and R2 value shown on chart. (b and c) Variant read
percentages for the pool data (gray circles) and the variant read percentages for the pool data after the subtractive correction with the single-
sample control data (black circles) are shown together in each panel. The “repeat region” is boxed in black line. (b) 50-pool control data.
Variant detection read cutoﬀ value of 0.5% is the solid horizontal black line. The horizontal dotted lines mark the singleton and doubleton
alleles’ expected variant read percentages of 1% and 2%, respectively. (c) Caucasian pool P2 data. Variant detection read cutoﬀ value of 1%
is the solid horizontal black line. The horizontal dotted lines mark the singleton and doubleton alleles’ expected variant read percentages of
1.7% and 3.4%, respectively.
assay [21]. Exon 13 contains c.2307G>T variant and exon
15 contains c.2712C>G variant (RET amplicon positions
5153 and 6943, respectively, Tables 1 and 2). Intron 9 was
chosen since it contains three NGS-detected variants in close
proximity at RET amplicon positions 117, 156, and 174
(c.1760−197G>T, c.1760−158C>G, and c.1760−140C>G,
resp.), and also to verify the novel c.1760−158C>G variant
detected in Caucasian pool P2 which had the lowest variant
read percentage of 1.12% (expected 1.72% singleton read
frequency within that pool of 29 samples). Since some
homozygous variants can have similar melting proﬁles as
the wild-type sample [22], a technique that spikes wild-
type DNA into the PCR reaction to allow distinction of
homozygous variants was performed on any sample that
appeared wild-type after testing in the ﬁrst HRM assay. This
technique identiﬁed four homozygous variants in RET exon
15andonehomozygousvariantinRET intron9(Figure 2(b)
and data not shown). The HRM determined allele frequencyJournal of Thyroid Research 7
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Figure 2: Variant validation within RET intron 9 by high-resolution melting analysis. The ﬂuorescence diﬀerence plot (ﬂuorescence
diﬀerenceversustemperature)ofthemeltingcurvedataisshownineachpanel.(a) RET intron9.Theblacklinesaresamplesofhomozygous
wild-type sequence. Data from four samples with unique variants within intron 9 are shown: heterozygous at amplicon position 156 (green
trace, c.1760−158C>G), heterozygous at 174 (red trace, c.1760−140C>G), heterozygous at 117 (pink trace, c.1760−197G>T), and a sample
heterozygous at both positions 117 and 174 (light blue). (b) Intron 9 with wild-type DNA spiked into the PCR reaction to help diﬀerentiate
homozygous variants. One sample with a homozygous variant at position 174 with (“+spike”) and without wild-type DNA spiked in is
shown (blue traces) compared to a 174 heterozygous (red trace) and wild-type sample (black trace).
Table 2: Validation of several variants and comparison of NGS and HRM determined variant allele frequencies.
Pool No. of samplesa 117b in intron 9 156 in intron 9 174 in intron 9 5153 in exon 13 6943 in exon 15
NGSc HRMc NGS HRM NGS HRM NGS HRM NGS HRM
Ethnic 23 6.2% 6.5% 0.01% 0.00% 6.7% 8.7% 62% 63% 12% 13%
P1 27 5.6% 5.6% 0.01% 0.00% 0.0% 0.0% 74% 74% 13% 19%
P2 29 8.1% 8.6% 1.12%d 1.70% 0.0% 0.0% 69% 72% 14% 16%
aA total of 79 samples were individually tested for variants by HRM analysis for three regions of the RET gene (which analyzed the 5 NGS-detected variant
positions shown in this table).
bRET amplicon position shown, see Table 1 for more information on each variant change.
cNGS: illumina genome analyzer determined allele frequency (variant read percentage) from a pooled sample set. HRM: high-resolution melting analysis
determined allele frequency, where each individual in the pool was tested separately for variation.
dLowest NGS variant read percentage for all pools. This suspected variant was veriﬁed as a singleton allele within Caucasian pool P2 by HRM and Sanger
sequencing.
correlatedwellwiththeNGSvariantreadpercentageforeach
variant in each pool (Table 2). The variant with the lowest
read percentage (position 156 in P2, 1.12%) was veriﬁed as
present and heterozygous in one sample within Caucasian
pool P2.
4. Discussion
This paper describes RET proto-oncogene sequence vari-
a t i o nd e t e c t e di na nM E N 2u n a ﬀected cohort of 136
individuals. The previous genome analyzer sequenced 50-
pool library [17, 18] was used to control for the detection of
variations with low read frequency, and all known variants
were detected >0.5% variant reads. With similar error rates
between genome analyzer lanes of the same run [11, 12,
17, 19, 20, 23, 24], the singleton variants in a less than or
equal to 30-sample pool should be accurately detected above
background error using our previously determined cutoﬀ
value of >1% variant read frequency. The single sample
controlledforbackground sequencing errorrates across each
RET sequence position and was used for the subtractive
correction method of variant detection for pools [17, 18].
The majority of the MEN2 unaﬀected cohort were of
Caucasian ethnicity, while 23 samples were non-Caucasian
(ethnic pool) and were used to identify RET variants within
a more ethnically diverse sample set. The 136 samples were
distributed into ﬁve nonindexed pools and were sequenced
in ﬁve separate ﬂow cell lanes. Using previously described
protocols for bioinformatics, subtractive correction, and
variant read cutoﬀ value of >1% [17, 18], a total of 61 RET
variants were detected within the MEN2 unaﬀected cohort.
Twenty of these variants were novel, not in NCBI dbSNP
132 (which includes 1000 Genome data) or found in our
previous sample pooling studies on the RET proto oncogene8 Journal of Thyroid Research
[17, 18]. Many of these novel changes were speciﬁc to either
the Caucasian or ethnic samples and were of low variant read
frequency, so they were likely to be singleton or doubleton
variants within the pools. Several variants were veriﬁed by
HRM and Sanger sequencing, including the novel change
(c.1760−158C>G) with the lowest variant read percentage
(1.12%).
The RET MEN2 database developed by the author so far
has147entries,ofwhich74areknownpathogenicmutations
and 62 are variants of uncertain signiﬁcance. This database
has been used as a model for predictions of phenotypic
severity of variants of unknown clinical signiﬁcance within
the RET proto oncogene [30]. RET sequence variation data
for these MEN2 unaﬀected cohorts will be added to the
MEN2 RET database [8]. This variant data will help in
medicalinterpretationofvariationsfoundinthisRET proto-
oncogene region using methods such as Sanger sequencing
orNGS(targetedtotheRET gene,thewholeexome,orwhole
genome sequencing). Any RET sequence change detected
in individuals with a family history of MEN2 symptoms or
where MEN2 is suspected (patient with apparent sporadic
MTC or Pheochromocytoma) can be compared to the
available RET MEN2 database, and also to the benign RET
sequence variation present in the large cohort of unaﬀected
individuals that was generated in this paper. This highlights
the importance of clinically relevant databases with not
only known pathogenic changes, but also the inclusion of
known benign changes for clinical test interpretation. The
MEN2 unaﬀected cohort’s variant results can also be used in
comparison to variants detected in suspected MEN2 patients
for case reports. A potential problem for genetic test design
is unknown variants present in the location of the PCR
primers, Sanger sequencing primers, or melting analysis
probes. Results from this unaﬀected population will help
with genetic test design, so that primers, and probes will not
be designed over the known RET sequence changes.
This paper presents sequence variation detection meth-
ods that could be used for other genes and analysis for
speciﬁc cohorts (unaﬀected versus aﬀected, by diﬀerent
ethnicities, or those with speciﬁc symptoms of disease).
The resulting data can be added to locus-speciﬁc databases
to help interpret the pathogenicity of clinically detected
sequence variation. These validated methods can also apply
to other pooled samples (such as genetic locations for GWAS
followup or for testing-speciﬁc populations) and natural
pools (such as mitochondrial heteroplasmy or mixed tumor
populations).
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